Covid-19 roundup: Valneva defends vaccine in wake of unflattering booster study; Merck goes after Pfizer’s new antiviral — report
Falling way behind the frontrunners in delivering a Covid-19 vaccine, French biotech Valneva has placed high hopes on boosters.
Which may be why it is reacting strongly to a study suggesting that its candidate, VLA2001, was the only one out of seven that didn’t work well as a booster for volunteers who had doses of the Pfizer/BioNTech mRNA shot.
The company is trying to fire back Monday morning, days after results from the COV-Boost study were published in The Lancet.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.